#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Reflection of Progress in Hemophilia Treatment in Current WFH Recommendations

In June 2020, the new, third guidelines of the World Federation of Hemophilia (WFH) were introduced. They are based on the fact that in the past 5 years there has been significant progress in the management of hemophilia, mainly due to the introduction of new −⁠ even revolutionary −⁠ drugs into clinical practice.
Source: Quality Life Even with Hemophilia 30. 9. 2020

News Emicizumab Changes the Lifestyle of Patients with Hemophilia A

At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of emicizumab on the lifestyle of people with hemophilia A.
Source: Quality Life Even with Hemophilia 30. 9. 2020

News Genetic Testing in Non-Small Cell Lung Cancer -⁠ Clinical Practice Experience

Targeted therapy has brought significant improvements to certain groups of patients with non-small cell lung cancer (NSCLC). Selecting patients who will benefit from targeted therapy can be performed using molecular profiling with next-generation sequencing (NGS) techniques. However, we still lack sufficient data on the feasibility and results of such profiling in real-world clinical practice, which was the focus of an analysis recently published in The Oncologist.
Source: Genetic Profile and Treatment of NSCLC 30. 9. 2020

News Remarkable Findings from the Subanalysis of the Efficacy and Safety of Teriflunomide in the Chinese Population with MS in Relation to Global Results

Teriflunomide, from the group of disease-modifying drugs (DMDs), intended for the treatment of patients with multiple sclerosis (MS), inhibits the proliferation of lymphocytes. As a result, fewer lymphocytes that could damage the CNS pass through the blood-brain barrier. The efficacy and safety of teriflunomide in the global population were examined in the multinational randomized double-blind placebo-controlled TOWER study, with an interesting subanalysis published by Chinese authors.
Source: Multiple Sclerosis 24. 9. 2020

News Dynamics of Allergy Development in Children

The prevalence of allergic diseases in children in developed countries has been steadily increasing in recent decades. Slovak authors attempted to describe the dynamics of the development of allergic symptoms in a prospective cohort of children who developed atopic dermatitis, rhinoconjunctivitis, wheezing, urticaria, or food allergy within the first 5 years of life.
Source: Allergic Reactions 1. 10. 2020

News Ceftarolin Fosamil in Patients with Complicated Skin and Soft Tissue Infections Admitted to ICU

In a recently published data analysis from the COVERS 3 study, the antibiotic ceftarolin fosamil was evaluated in patients with complicated skin and soft tissue infections (cSSTI) admitted to the intensive care unit (ICU), and its effectiveness was compared with patients with the same diagnosis and treatment who did not require ICU admission.
Source: Anti-Infectives 17. 12. 2020

News How Common is Alpha-1 Antitrypsin Deficiency?

What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.
Source: Deficiency of Alpha-1-Antitrypsin 17. 12. 2020

News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?

The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?
Source: Multiple Sclerosis 17. 12. 2020

News How did alemtuzumab fare in real clinical practice?

A study published by authors from the University of Massachusetts in January this year in the journal Multiple Sclerosis and Related Disorders focused on the effectiveness and safety of alemtuzumab. How did it fare in real clinical practice?
Source: Multiple Sclerosis 11. 6. 2021

News Reduction of LDL Cholesterol in the Prevention of Cardiovascular Morbidity and Mortality –⁠ Results of a Large Meta-Analysis

Elevated LDL cholesterol (LDL-c) is one of the main causes of atherosclerosis. The meta-analysis presented below examined the effect of reducing its levels on the risk of cardiovascular (CV) morbidity and mortality.
Source: Chronic Heart Failure and Lipidology 11. 6. 2021

News Can antihypertensive treatment also have a beneficial effect on neurocognitive functions?

Observational studies suggest that a desirable side effect of AT1 receptor blockers for angiotensin II (sartans) could be cognitive protection of patients. A randomized study published last year evaluated the potential positive impact of candesartan and lisinopril on neurocognitive functions in older patients with mild cognitive impairment (MCI).
Source: Sartans in the Treatment of Hypertension 14. 6. 2021

News Are there mutual interactions between candesartan and amlodipine in the combination therapy of hypertension?

Monotherapy is often insufficient in the treatment of hypertension; however, combining antihypertensives with different mechanisms of action can be complicated by their mutual interactions. Therefore, a study by South Korean authors examined the pharmacokinetic interactions between candesartan and amlodipine, substances that are commonly used together in combined treatment.
Source: Sartans in the Treatment of Hypertension 14. 6. 2021

News Empagliflozin in the Treatment of Patients with Chronic Heart Failure

Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization due to heart failure and the risk of severe renal events in patients with type 2 diabetes mellitus. The efficacy of the SGLT2 inhibitor empagliflozin directly in the treatment of patients with chronic heart failure with reduced ejection fraction was evaluated in the EMPEROR-Reduced clinical study, the recently published results of which we summarize in the following article.
Source: Heart Failure 7. 12. 2021

News Reducing Cardiovascular Risk in Diabetics Through Hypertension Treatment

The presence of hypertension in patients with diabetes worsens overall cardiovascular (CV) prognosis and increases the prevalence of chronic renal failure. Adequate treatment of hypertension can significantly influence the development and severity of these complications. What target blood pressure (BP) values should we aim for in diabetics, which antihypertensive therapy to choose, and why not forget about 24-hour BP monitoring?
Source: Diabetes 21. 6. 2021

News Administration of Low-Molecular-Weight Heparin After Hemorrhagic Stroke: What Is the Appropriate Timing?

Hemorrhagic stroke (HS) is a condition that raises doubts and concerns about anticoagulation. Is early prevention of thromboembolic complications appropriate?
Source: Thromboprophylaxis 30. 9. 2021

1 31 32 33 34 35 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#